Is AFMDQ or XYLD a better dividend investment in 2026?

AFMDQ currently yields 1000000.00% with a 5% 5-year dividend growth rate. XYLD yields 10.98% with 0.5% growth. The better choice depends on your goal: AFMDQ offers higher current income.

What is the dividend yield difference between AFMDQ and XYLD?

AFMDQ has a forward dividend yield of 1000000.00% ($2.00/share annually). XYLD yields 10.98% ($4.30/share annually). The yield gap is 999989.02 percentage points.

Home › Compare › AFMDQ vs XYLD

AFMDQ vs XYLD: Dividend Comparison 2026

AFMDQ yields 1000000.00% · XYLD yields 10.98%● Live data

vsPost on X →

After 10 years · $10,000 invested · DRIP enabled

🏆 AFMDQ wins by $4.7683925249533696e+36M in total portfolio value

INVESTMENT

TIME HORIZON10 years

AFMDQ

● Live price

1000000.00%

Share price

$0.00

Annual div

$2.00

5Y div CAGR

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$4.7683925249533696e+36M

Annual income

$4,767,454,694,456,067,000,000,000,000,000,000,000,000,000.00

Full AFMDQ calculator →

XYLD

Global X S&P 500 Covered Call ETF

● Live price

10.98%

Share price

$39.13

Annual div

$4.30

5Y div CAGR

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$25.3K

Annual income

$3,219.02

Full XYLD calculator →

Portfolio growth — AFMDQ vs XYLD

📍 AFMDQ pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis Period	AFMDQ	XYLD
2008–2009 GFC	— No data	— No data
2020 Q1–Q2 COVID	— No data	— No data
2022 Q4 Rate Hike	— No data	— No data

Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.

📅

Dividend Calendar Overlap

Combined, AFMDQ + XYLD cover 0 of 12 months — good coverage

Jan

—

Feb

—

Mar

—

Apr

—

May

—

Jun

—

Jul

—

Aug

—

Sep

—

Oct

—

Nov

—

Dec

—

AFMDQ pays

XYLD pays

Both pay

Neither

💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

AFMDQ

Annual income on $10K today (after 15% tax)

$85,000,000.00/yr

After 10yr DRIP, annual income (after tax)

$4,052,336,490,287,657,000,000,000,000,000,000,000,000,000.00/yr

XYLD

Annual income on $10K today (after 15% tax)

$933.63/yr

After 10yr DRIP, annual income (after tax)

$2,736.17/yr

At 15% tax rate, AFMDQ beats the other by $4,052,336,490,287,657,000,000,000,000,000,000,000,000,000.00/year in after-tax income after 10 years on $10,000

⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of AFMDQ + XYLD for your $10,000?

AFMDQ: 50%XYLD: 50%

100% XYLD50/50100% AFMDQ

Portfolio after 10yr

$2.3841962624766848e+36M

Annual income

$2,383,727,347,228,033,600,000,000,000,000,000,000,000,000.00/yr

Blended yield

99.98%

📊

Analyst Conviction Gap

Where Wall Street is most bullish on AFMDQ right now

AFMDQ

Analyst Ratings

Buy

Hold

Consensus: Buy

Price Target

$7.50

+3749900.0% upside vs current

Range: $5.00 — $10.00

Altman Z

-25.7

Piotroski

1/9

XYLD

No analyst data

Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.

🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

AFMDQ buys

XYLD buys

No recent congressional trades found for AFMDQ or XYLD in the last 90 days.

STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →

MetricAFMDQXYLD

Forward yield	1000000.00% ✓	10.98%
Annual dividend / share	$2.00	$4.30 ✓
Payout ratio	50%	50%
1-year div growth	0%	0%
5-year div CAGR	0%	0%
Portfolio after 10y	$4.7683925249533696e+36M	$25.3K ✓
Annual income after 10y	$4,767,454,694,456,067,000,000,000,000,000,000,000,000,000.00 ✓	$3,219.02
Total dividends collected	$4.7683311610149396e+36M	$19.6K ✓
Payment frequency	quarterly	monthly
Sector	Stock	ETF

Year-by-year: AFMDQ vs XYLD ($10,000, DRIP)

Year	AFMDQ Portfolio	AFMDQ Income/yr	XYLD Portfolio	XYLD Income/yr	Gap
1← crossover	$100,010,700	$100,000,000.00	$10,818	$1,098.39	+$100.00M → AFMDQ
2	$934,786,450,701	$934,679,439,252.34	$11,738	$1,222.51	+$934786.44M → AFMDQ
3	$8,165,787,108,578,292	$8,164,786,887,076,042.00	$12,774	$1,364.64	+$8165787108.57M → AFMDQ
4	$66,665,884,190,957,650,000	$66,657,146,798,751,470,000.00	$13,944	$1,527.86	+$66665884190957.63M → AFMDQ
5	$508,662,171,058,048,100,000,000	$508,590,838,561,963,700,000,000.00	$15,270	$1,715.87	+$508662171058048128.00M → AFMDQ
6	$3,627,235,248,428,489,700,000,000,000	$3,626,690,979,905,457,600,000,000,000.00	$16,775	$1,933.09	+$3.62723524842849e+21M → AFMDQ
7	$24,173,681,159,150,610,000,000,000,000,000	$24,169,800,017,434,790,000,000,000,000,000.00	$18,490	$2,184.87	+$2.417368115915061e+25M → AFMDQ
8	$150,567,402,861,454,640,000,000,000,000,000,000	$150,541,537,022,614,370,000,000,000,000,000,000.00	$20,450	$2,477.63	+$1.5056740286145463e+29M → AFMDQ
9	$876,477,100,281,847,600,000,000,000,000,000,000,000	$876,315,993,160,785,800,000,000,000,000,000,000,000.00	$22,697	$2,819.19	+$8.764771002818475e+32M → AFMDQ
10	$4,768,392,524,953,369,600,000,000,000,000,000,000,000,000	$4,767,454,694,456,067,000,000,000,000,000,000,000,000,000.00	$25,280	$3,219.02	+$4.7683925249533696e+36M → AFMDQ

AFMDQ vs XYLD: Complete Analysis 2026

AFMDQ — Stock

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States and Germany. The company's lead product candidates include AFM13 that has completed Phase 2 clinical trial for CD30-positive lymphoma, Phase Ib clinical trial for hodgkin lymphoma, and completed Phase IIb clinical study for peripheral T-cell lymphoma; AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; and AFM28, an innate cell engager (ICE), which is in preclinical development for the treatment acute myeloid. It develops AFM32, an ICE candidate that is in preclinical development for the treatment of solid tumors. It has collaboration with Artiva Biotherapeutics to develop the combination of acimtamig and AlloNK; license and strategic collaboration agreement with Roivant Sciences Ltd. to develop and commercialize novel ICE molecules, including AFM32, in oncology; and strategic collaboration agreement with Genentech for the development of certain product candidates, which includes novel NK cell engager-based immunotherapeutics to treat multiple cancers. The company was formerly known as Affimed Therapeutics B.V. and changed its name to Affimed N.V. in October 2014. Affimed N.V. was founded in 2000 and is headquartered in Mannheim, Germany.

Full AFMDQ Calculator →

XYLD — ETF

The Global X S&P 500 Covered Call ETF (XYLD) seeks to provide investment results that correspond generally to the price and yield performance, before fees and expenses, of the Cboe S&P 500 BuyWrite Index.

Full XYLD Calculator →

📬

Get this AFMDQ vs XYLD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

AFMDQ vs SCHD AFMDQ vs JEPI AFMDQ vs O AFMDQ vs KO AFMDQ vs MAIN AFMDQ vs QYLD AFMDQ vs JEPQ AFMDQ vs RYLD

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.